IVRO (Invitro International) Current Accrued Expense: $0.05 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invitro International Current Accrued Expense?

Invitro International IVRO +1.33% Current Accrued Expense is $0.05 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Invitro International's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.05 Mil.

Invitro International's quarterly Current Accrued Expense declined from Sep. 2025 ($0.06 Mil) to Dec. 2025 ($0.05 Mil) but then increased from Dec. 2025 ($0.05 Mil) to Mar. 2026 ($0.05 Mil).

Invitro International's annual Current Accrued Expense increased from Sep. 2096 ($0.00 Mil) to Sep. 2024 ($0.04 Mil) and increased from Sep. 2024 ($0.04 Mil) to Sep. 2025 ($0.06 Mil).

Invitro International Current Accrued Expense Related Terms

Invitro International Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Invitro International's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitro International Current Accrued Expense Chart

Invitro International Annual Data
Trend Feb90 Feb91 Sep92 Sep93 Sep94 Sep95 Sep96 Sep24 Sep25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.04 0.06

Invitro International Quarterly Data
Sep94 Dec94 Mar95 Jun95 Sep95 Dec95 Mar96 Jun96 Sep96 Dec96 Mar97 Jun97 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.05 0.06 0.05 0.05

Invitro International Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.05 Mil mean?
Invitro International (IVRO) has a Current Accrued Expense of $0.05 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Invitro International and its competitors.
Is Invitro International's Current Accrued Expense too high?
Invitro International's current Current Accrued Expense is $0.05 Mil.
How does Invitro International's Current Accrued Expense compare to IDTA and PRPH?
Invitro International's Current Accrued Expense of $0.05 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Invitro International and its competitors. Invitro International's current Current Accrued Expense is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Current Accrued Expense is $0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Invitro International (IVRO), the current Current Accrued Expense is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invitro International Business Description

Address 330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.